Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus chemotherapy with or without celecoxib in advanced NSCLC
ChiCTR2000041072Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of celecoxib and pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Objective response rate, Progression-free survival and 1 more. Started Jan 2021; status: recruiting.
02
Drugs
celecoxibpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000041072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041072.